Kyverna Therapeutics (KYTX) Non Operating Income (2023 - 2026)
Kyverna Therapeutics posted quarterly Non Operating Income of -$21000.0 for Q1 2026, down 100.76% year-on-year from $2.8 million in Q1 2025, and down 223.53% on a QoQ basis from $17000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Non Operating Income data on file, last reported at -$21000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 100.76% year-over-year to -$21000.0; the trailing twelve-month figure through Mar 2026 stood at -$78000.0 (up 98.32% YoY), and the FY2025 full-year result was -$85000.0, up 5.56% from the prior year.
- Non Operating Income for Q1 2026 stood at -$21000.0, down from $17000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $4.3 million in Q3 2024 and bottomed at -$11.7 million in Q4 2024.
- The 4-year median for Non Operating Income is -$13000.0 (2023), against an average of -$266000.0.
- Peak annual rise in Non Operating Income reached 88933.33% in 2024, while the deepest fall reached 742.24% in 2024.
- A 4-year view of Non Operating Income shows it stood at -$1.4 million in 2023, then slumped by 742.24% to -$11.7 million in 2024, then surged by 100.15% to $17000.0 in 2025, then slumped by 223.53% to -$21000.0 in 2026.
- The last three Non Operating Income figures came in at -$21000.0 (Q1 2026), $17000.0 (Q4 2025), and -$53000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | -21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | -11.67 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Jun 30, 2024 | -23,000.00 |
| Mar 31, 2024 | 2.67 Mn |
| Dec 31, 2023 | -1.39 Mn |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2023 | -7,000.00 |
| Mar 31, 2023 | -3,000.00 |